A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: A randomized crossover study in healthy human volunteers

Drug Research

Volumn 63, Issue 4, 2013, Pages 177-184

  Gorain, B ^a   Choudhury, H ^a   Halder, D ^a   Sarkar, A K ^a   Sarkar, P ^a   Biswas, E ^a   Ghosh, B ^b   Pal, T K ^a  

^a JADAVPUR UNIVERSITY   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

amlodipine; bioavailability; hydrochlorothiazide; hypertension; pharmacokinetics; telmisartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE; TELMISARTAN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG STRUCTURE; ESSENTIAL HYPERTENSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY;

EID: 84877773464     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1334882     Document Type: Article

References (21)

1. Manjula Devi A. S., Sriram S., Rajalingam B. et al. Evaluation of the Rationality of Fixed Dose Combinations of Cardiovascular drugs in a Multispecialty Tertiary care hospital in Coimbatore, Tamilnadu, India. Hygeia J D Med: 2012; 4 51 58
2. Chobanian A. V., Bakris G. L., Black H. R. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension: 2003; 42 1206 1252 (Pubitemid 37553153)
3. ESH/ESC Hypertension Guidelines Committee Practic guidelines for primary care physicians: 2003 ESH/ESC Hypertension Guidelines. J Hypertens: 2003; 21 1779 1786
4. Maladkar M., Verma V. K., Narsikar K. A. et al. Triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the treatment of essential hypertension. Open Journal of Internal Medicine: 2012; 2 67 71
5. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretic in hypertension. Expert Rev Cardiovasc Ther: 2003; 1 43 50
6. Kalra S., Kalra B., Agrawal N. Combination therapy in hypertension: An update. Diabetology & Metabolic Syndrome: 2010; 2 44
7. st August 2012
8. Plosker G. L., White W. B. Telmisartan/Hydro chlorothiazide: A review of its use as fixed-dose combinations in essential hypertension. Drugs: 2008; 68 1877 1899
9. Lacourcière Y., Neutel J. M., Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther: 2005; 27 1795 1805 (Pubitemid 41815230)
10. Venkata Ram S. C. Antihypertensive Efficacy of Angiotensin Receptor Blockers in Combination with Hydrochlorothiazide: A Review of the Factorial-Design Studies. The Journal of Clinical Hypertension: 2004; 6 569 577
11. Osvaldo K., Wille O., Decio N. et al. The "LOTHARo" Study: Evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arq Bras Cardiol: 2006; 86 1
12. Oparil S., Melino M., Lee J. et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multi-center, randomized, double-blind, 12-week, parallel-group study. Clin Ther: 2010; 32 1252 1269
13. Ram C. V., Sachson R., Littlejohn T. et al. Management of hypertension in patients with diabetes using an amlodipine, olmesartan medoxomil, and hydrochlorothiazide-based titration regimen. Am J Cardiol: 2011; 107 1346 1352
14. st August 2012
15. st August 2012
16. st August 2012
17. st August 2012
18. Nation R. L., Sansom L. N. Bioequivalence requirements for generic products. Pharmacol Ther: 1994; 62 41 55 (Pubitemid 24234857)
19. th November 2011
20. st August 2012
21. EMEA Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. London: European Medicines Agency (EMEA): 2008; Available from: URL http://www.ema.europa.eu/docs/en-GB/document-library/- Scientific-guideline/2009/09/WC500003011.pdf